Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 228 от 240

Активно (без набиране) Фаза 1

NFL LONG Prospective Study

Concussion, Brain

The purpose of this 5-year prospective research study is to characterize the association between concussions, sub-concussive exposure, and long-term neurologic health outcomes in former NFL players. To achieve the study aims, the investigators will conduct detailed research visits that include clinical outcome assessments, blood-based biomarkers, advanced magnetic resonance imaging (MRI), positron emission tomography (PET) using investigational tracers and genetic testing. Ultimately, the goal of this study is to translate the findings from this study into clinical, interventional studies for at risk former NFL players.

Начало: 12.03.2020 Край: 01.08.2028 Възраст: 50–70 г.

United States University of North Carolina, Chapel Hill NCT04263337

Активно (без набиране) Фаза 2

AG-120 in People With IDH1 Mutant Chondrosarcoma

Chondrosarcoma Chondrosarcoma, Grade 2 Chondrosarcoma, Grade 3 IDH1 Gene Mutation

This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

Начало: 04.03.2020 Край: 01.03.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT04278781

Активно (без набиране) Фаза 2

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Metastatic Prostate Cancer

This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether the study treatment works better than the standard treatment.

Начало: 03.03.2020 Край: 01.09.2026 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT04262154

Активно (без набиране) Фаза 1/2

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

HCC

This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.

Начало: 01.03.2020 Край: 29.11.2028 Възраст: от 18 г. Лечение

New Zealand, United States Geneos Therapeutics NCT04251117

Активно (без набиране) Фаза 1

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Diabetes Mellitus, Type 1

The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a therapeutic option for T1D patients and potentially other autoimmune disorders.

Начало: 27.02.2020 Край: 30.05.2027 Възраст: 18–40 г.

United States Medical University of South Carolina NCT04061746

Активно (без набиране)

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Breast Cancer

A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.

Начало: 21.02.2020 Край: 30.06.2026 Възраст: от 18 г.

Argentina, Brazil, Chile +7 Hoffmann-La Roche NCT04158258

Активно (без набиране) Фаза 1

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Glioblastoma Multiforme

This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and spartalizumab in treating patients with recurrent glioblastoma multiforme (GBM). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor to more precisely target the cancer. Monoclonal antibodies, such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and spread. Giving stereotactic radiosurgery together with immunotherapy may be a better treatment for GBM.

Начало: 18.02.2020 Край: 01.09.2026 Възраст: от 18 г.

United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopk NCT03961971

Активно (без набиране)

Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patients With Myocardial Infarction

Myocardial Infarction Vascular Stiffness Heart Failure

Risk assessment after myocardial infarction is critical in daily practice and evolution toward heart failure especially diastolic heart failure remains a key issue. All consecutive patients with myocardial infarction (either STEMI or NSTEMI but excluding type 2 MI) presenting at university hospital of Lille within 48 hours after symptom onset will be recruited in the RIGID-MI registry. The RIGID-MI study proposes to deeply evaluate at 1 month after MI: peripheral vascular disease, vascular stiffness, ventriculo-arterial coupling and other usual risk factors. The main objective is to identify clinical, biological and imaging parameters associated with poor prognosis, especially evolution toward diastolic heart failure, recurrence of MI, and bleeding.

Начало: 17.02.2020 Край: 01.03.2030 Възраст: от 18 г.

France University Hospital, Lille NCT04058782

Активно (без набиране)

Sleep Intervention for Chronic Insomnia Using Virtual Reality Pilot Study

Insomnia Chronic Pain, Chronic

Sleep disturbances are common among chronic pain patients, with reports typically ranging from 50-70% of patients reporting sleep difficulties. It is well documented that, alongside a high comorbidity with chronic pain, chronic insomnia also has high comorbidity with, and is a risk factor for, developing an anxiety disorders. This clinical trial will examine the effects of virtual reality (VR) meditation environments on patients with pain- and insomnia-related anxiety. The purpose of this study is to examine the benefits of using VR meditation with patients with chronic pain and chronic sleep disturbance so that clinicians can more effectively treat core causes to symptoms and reduce counterproductive therapies. Research objectives include: 1. To examine the clinical and health characteristics, including sleep, pain, fatigue, cognitive abilities, and cardiovascular health in patients with chronic pain. 2. To examine changes in the primary clinical outcomes, including chronic pain, complaints of poor sleep, and fatigue. 3. To examine changes in the secondary clinical outcomes, including mood, daytime functioning, cognitive functioning, and cardiovascular health. 4. To examine the mechanistic variables, including arousal (heart rate variability, HRV) and CS (thermal response).

Начало: 09.02.2020 Край: 30.12.2026 Възраст: от 18 г.

United States University of Missouri-Columbia NCT04253691

Активно (без набиране)

Assisted Suicide in Switzerland

Assisted Suicide

Background: Researchers want to learn more about how the Swiss model of assisted suicide works. To do this, they have interviewed 25 Swiss experts. The researchers will draw on research in the fields of ethics, law, and medicine to analyze the transcripts. Objective: To describe the practice of assisted suicide in Switzerland and to study how the policy is carried out, how the right-to-die societies work, and the ethical implications of the practice. Eligibility: Swiss experts in the field of assisted suicide Design: The study includes 25 interviews that have already been conducted. The participants were: * academics * doctors and others in medical care * a government official * representatives of right-to-die societies. Researchers will analyze the data using qualitative methods. Two researchers will develop a coding scheme and code the texts and analyze the data.

Начало: 03.02.2020 Край: 31.01.2027 Възраст: от 18 г.

United States National Institutes of Health Clinical Center (CC) NCT04261088

Активно (без набиране) Фаза 2

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

Acromegaly

A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.

Начало: 29.01.2020 Край: 01.03.2028 Възраст: 18–75 г.

Brazil, Germany, Greece +4 Crinetics Pharmaceuticals Inc. NCT04261712

Активно (без набиране) Фаза 2

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Metastatic Soft Tissue Sarcoma Advanced Soft Tissue Sarcoma

This is an open-label, non-randomized, single-institution, single arm Phase II study conducted using a Simon two-stage design with an additional safety lead-in. The overall objective is to determine the efficacy of combination doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1884 and anti-PD-1 antibody AGEN2034. The investigators will estimate the progression-free survival rate at 6 months (PFS6mo) of doxorubicin plus AGEN1884/AGEN2034 in comparison to historical PFS6mo with doxorubicin monotherapy, calculated as the mean from two large randomized Phase 3 clinical trials.

Начало: 28.01.2020 Край: 31.12.2027 Възраст: 18–100 г.

United States University of Colorado, Denver NCT04028063

Активно (без набиране)

M7824 Related Adverse Effects in Adults With Cancer

Neoplasms Skin Neoplasms

Background: Immunotherapy drugs use a person s own immune system to help fight cancer. These drugs work better for some people than others. The drug M7824 has helped some people with cancer. But it can cause side effects. Researchers want to learn all the side effects that M7824 can cause. Once they do, they can prevent or reduce these side effects in future cancer treatments. This will lead to better overall outcomes for people with cancer. Objective: To make a thorough list of adverse events in people with cancer being treated with systemic therapies including M7824 at the National Cancer Institute (NCI). Eligibility: Participants previously enrolled in NCI protocols #15-C-0179 and #18-C-0056 Design: All needed data have already been collected. These data are stored in existing records and databases. Researchers will review the medical records of adults with cancer who were enrolled in the above protocols. The data collected will be relevant to the specific objectives being addressed. Data will be collected only if 2 conditions are met. One, the principal investigator gave permission for use of the data gathered in the trial. Two, the participants of the trial did not opt out of future use of the data. Other protocols may be added. This will be done with an amendment. ...

Начало: 28.01.2020 Край: 01.11.2027 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT04267861

Активно (без набиране) Фаза 3

MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial

Giant Cell Arteritis

Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. It is characterized by a granulomatous inflammation of the wall of large vessels, involving especially the aorta and extra-cranial branches of the external carotid, with vascular remodelling leading to ischemic manifestations such as temporal headaches, jaw claudication, scalp tenderness and visual loss. Most patients with GCA also present signs of systemic inflammation, including weight loss, fatigue and fever, together with an increased erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level. Glucocorticoids (GC) are the cornerstone of the treatment of GCA. They are very effective and are usually given for 18-24 months to avoid relapses. Therefore, most patients develop GC-related complications that cause morbidity and disability. GC sparing strategies are thus required to improve the treatment of GCA. * A 12-month treatment with tocilizumab (TCZ) has recently been shown to be effective in inducing and maintaining remission of GCA, with a dramatic GC-sparing effect. However, TCZ is an expensive drug; TCZ suppresses CRP synthesis and ESR elevation so that it is difficult to monitor patients; and importantly around 40% of patients relapse within 6 months after TCZ discontinuation, whether prescribed for 12 months or 4 months. * In association with 6 months of prednisone, 10 mg/week of methotrexate (MTX) for 24 months lowers the risk of relapse at 24 months from 84% to 45%. Therefore, the hypothesis is that 12 months of MTX treatment (0.3 mg/Kg/week, without exceeding 20 mg/week) is not inferior to 12 months of TCZ (162 mg SC/week) in term of prevention of relapse at 18 months. The MTX strategy might be more cost effective than TCZ. In the present study, it is proposed to compare MTX versus TCZ in a multicenter randomized controlled trial. Moreover, the economic consequences associated with the use of MTX rather than TCZ will be also assess.

Начало: 27.01.2020 Край: 01.01.2027 Възраст: от 50 г.

France Centre Hospitalier Universitaire Dijon NCT03892785

Активно (без набиране) Фаза 3

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Moderate Chronic Plaque Psoriasis Severe Chronic Plaque Psoriasis Mixed Guttate/Plaque Psoriasis

The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.

Начало: 21.01.2020 Край: 02.07.2026 Възраст: 6–17 г.

Canada, Puerto Rico, United States UCB Biopharma SRL NCT04123795

Активно (без набиране) Фаза 2

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Neoplasms

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

Начало: 31.12.2019 Край: 31.07.2026 Възраст: от 10 г.

Canada, France, Italy +4 USWM CT, LLC NCT03967223

Активно (без набиране)

The HPV 9-10 Trial: Early Initiation of HPV Vaccination

HPV

Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In this study, we will examine in a randomized trial whether earlier initiation of the vaccine at age 9-10 years will result in less parental refusal and higher rates of full vaccination at younger ages, before early sexual activity begins.

Начало: 23.12.2019 Край: 01.04.2027 Възраст: 9–13 г.

United States University of Colorado, Denver NCT04722822

Активно (без набиране) Фаза 3

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Начало: 23.12.2019 Край: 02.06.2026 Възраст: от 18 г.

Canada, France, Germany +7 UCB Biopharma SRL NCT04225871

Активно (без набиране) Фаза 2

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.

Начало: 20.12.2019 Край: 17.10.2026 Възраст: от 18 г.

United States Dan Zandberg NCT04080804

Активно (без набиране) Фаза 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Advanced Malignancies

This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).

Начало: 19.12.2019 Край: 01.07.2026 Възраст: от 18 г. Лечение

Australia, China, France +10 BeOne Medicines NCT04164199

1 … 226 227 228 229 230 … 240